The purpose of this transmittal is to outline policy changes that the District Medicaid program will implement effective September 1, 2022, to expand access to Hepatitis C treatment by eliminating existing barriers to orally administered Direct Acting Antivirals (DAAs) used in the current treatment of chronic Hepatitis C infections for Fee-for-Service (FFS) and Managed Care Plan (MCP) enrolled beneficiaries.